International Stem Cell Corp Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how International Stem Cell Corp (ISCO) performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

ISCO is a biotech company with two main sides. First, they are a researcher developing stem cell therapies for conditions like Parkinson’s disease, stroke, and brain injuries. Their "secret sauce" is a proprietary stem cell (hpSCs) derived from unfertilized human eggs. This technology aims to avoid the ethical issues of embryonic stem cells and the rejection risks of traditional transplants.

Second, they have a commercial business that generates cash by selling:

• Research Products: Over 200 types of human cells and specialized growth materials sold to labs and drug companies.
• Skincare: A line of anti-aging products called "Lifeline" that uses their stem cell extracts.

2. Financial performance: Stagnant growth

The most important takeaway is that revenue is flat. They generated $9.1 million in total revenue for 2025, exactly the same as in 2024.

Operating expenses remain much higher than their profit, leading to a loss of about $12.4 million this year. The company uses cash from their skincare and research products to pay for their $6.8 million in research and development. Because their medical treatments are still in testing, they currently earn zero revenue from their primary medical pipeline.

3. The "Going Concern" warning

This is a major red flag: auditors have expressed "substantial doubt" about ISCO’s ability to stay in business. At year-end, the company held only $1.2 million in cash, while their debts exceeded $15 million. They are burning through $800,000 to $1 million every month. Without new funding, they likely cannot pay their bills for more than 3–6 months.

4. Major wins and challenges

• Clinical Progress: They finished a Phase 1 trial for their Parkinson’s treatment. The 12-patient trial reported no safety issues. Patients showed a promising reduction in "OFF-Time," with some gaining an average of 2.5 hours of "ON-Time" per day.
• The Funding Gap: Because they aren't profitable, they survive by issuing debt and new shares. This leads to more shares being issued, which reduces your ownership percentage and potential earnings per share. In the last year, the share count grew by 15%.
• Customer Concentration: Their revenue is vulnerable. Their top three customers provide 42% of their research product sales. Losing even one of these clients would significantly hurt their cash flow.

5. Key risks

• Survival Risk: The company is technically insolvent. They rely entirely on creditors or new investors to keep the lights on.
• Regulatory Hurdles: The path to FDA approval is long and expensive. Future trials could cost $20 million to $50 million—money the company does not have.
• Market Sensitivity: They are trying to fund high-stakes medical research using the thin profits from a niche skincare brand.

6. The Bottom Line

ISCO is a high-risk, high-reward play. They have promising early safety data, but they are in a precarious financial spot. They are essentially a research lab struggling to survive on the modest cash flow of a skincare business.

Decision Checklist:

• Are you comfortable with extreme volatility? This stock is highly sensitive to funding news and clinical trial updates.
• Do you believe in the tech? The investment thesis relies entirely on the potential of their stem cell therapies to eventually reach the market or attract a larger partner.
• Can you handle dilution? Be aware that the company frequently issues new shares to stay afloat, which can lower the value of existing holdings.